Subscribe
e.g. organoids

US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (Lisocabtagene Maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application for Breyanzito expand its current indication to include the treatment of adult patients with relapsed or refractory CLL or SLL who received a prior Bruton tyrosine kinase inhibitor and B cell lymphoma 2 inhibitor.
[Bristol Myers Squibb]
Press Release
Published In
NewslettersHematopoiesis News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies

[FDA] The FDA has received reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
Cell Therapy NewsNewsletters
Read more

Modular Chimeric Cytokine Receptors with Leucine Zippers Enhance the Antitumour Activity of CAR T Cells via JAK/STAT Signaling

[Nature Biomedical Engineering] Investigators showed that replacement of the extracellular domains of heterodimeric cytokine receptors in T cells with two leucine zipper motifs provided optimal Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling.
Cell Therapy NewsNewsletters
Read more

CAR+ T Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

[blood] The authors presented the clinicogenomic characterization of a CARTITUDE-4 patient who developed a CAR+ T cell lymphoma post cilta-cel. Diagnostic and staging workup included biopsy analyses and FDG-PET scan.
Cell Therapy NewsNewsletters
Read more
Brought to you by